Recent Quotes (30 days)

You have no recent quotes
chg | %

Pivotal Therapeutics Inc  

(Public, CNSX:PVO)   Watch this stock  
Find more results for PVO
0.0000 (0.00%)
Oct 13 - Close
CNSX real-time data - Disclaimer
Currency in CAD
Range 0.03 - 0.05
52 week 0.02 - 0.11
Open 0.05
Vol. 81,725.00
Mkt cap 4.75M
P/E     -
Div/yield     -
EPS -0.05
Shares 95.01M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -1755.14%
Operating margin - -1883.34%
EBITD margin - -1849.58%
Return on average assets -375.56% -256.34%
Return on average equity - -
CDP Score - -


81 Zenway Blvd Unit 10
+1-905-8569797 (Phone)
+1-905-8562177 (Fax)

Website links


Pivotal Therapeutics Inc. (Pivotal) is a specialty pharmaceutical company. The Company specializes in cardiovascular science, focused on cardiovascular disease and overall health. Its lead prescription only medical food product, VASCAZEN, is used for the clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and who are deficient in blood Omega-3 fatty acids, Eicosapentaenoic Acid EPA) and Docosahexanenoic Acid (DHA) levels. VASCAZEN is a pharmaceutical formulation of EPA:DHA. Pivotal's OMAZEN is being commercialized in Canada for the maintenance of good health through elevating Omega- 3 fatty acid levels and Benefishial, which is targeting the direct to consumer market place and consists of six different products.

Officers and directors

John S. Gebhardt Independent Chairman of the Board
Age: 67
Rachelle MacSweeney President, Chief Operating Officer, Director
Eugenio G. Bortoluzzi Chief Executive Officer, Chief Financial Officer, Director
James J. Carey Independent Vice Chairman of the Board
George Jackowski Ph.D. Chief Scientific Officer, Director
Giuseppe Simeone Independent Director